Literature DB >> 12640380

Long-term outcome in children with Guillain-Barré syndrome.

Jiri Vajsar1, Darcy Fehlings, Derek Stephens.   

Abstract

OBJECTIVE: To determine the long-term sequelae and early predictors of sequelae for children with Guillain-Barré syndrome (GBS) after the introduction of intravenous gammaglobulin (IVIG). Study design A cross-sectional case series of children with GBS, at least 2 years after recovery, was performed. Manual muscle strength testing was done on 34 muscle groups. The functional independence measure was used to assess function. A chart review was completed, identifying acute factors that may predict long-term sequelae.
RESULTS: Forty-seven children with GBS were identified, of whom 30 received IVIG. Persisting long-term muscle weakness with at least one muscle group at a grade 6 level (muscle moves the joint against gravity but only minimal resistance to an applied force) was found in 23% of cases. Each patient had a perfect score on the functional independence measure. Long-term muscle weakness was predicted by young age (P =.03) and a rapid progression to maximal weakness (P =.03).
CONCLUSIONS: Despite the introduction of IVIG, 23% of children with GBS had evidence of long-term mild muscle weakness, with minimal impact on function. Young age and a rapid progression during the acute GBS period predicted long-term sequelae.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640380     DOI: 10.1067/mpd.2003.115

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

1.  Predictive factors for achieving independent walking in children with Guillain-Barre syndrome.

Authors:  Mohammad Barzegar; Vahideh Toopchizadeh; Mohammad H K Maher; Paria Sadeghi; Fatemeh Jahanjoo; Alireza Pishgahi
Journal:  Pediatr Res       Date:  2017-05-17       Impact factor: 3.756

Review 2.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

3.  Weakness and the inability to ambulate in a 14-month-old female: a case report and concise review of guillain-barre syndrome.

Authors:  Scott A Bloch; Mahsa Akhavan; Jahn Avarello
Journal:  Case Rep Emerg Med       Date:  2013-01-30

4.  Autoimmune neuromuscular disorders in childhood.

Authors:  Hugh J McMillan; Basil T Darras; Peter B Kang
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

5.  Functional outcomes and efficiency of rehabilitation in a national cohort of patients with Guillain-Barré syndrome and other inflammatory polyneuropathies.

Authors:  Roxana Alexandrescu; Richard John Siegert; Lynne Turner-Stokes
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

6.  Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis and Guillain-Barre Syndrome in a 16-Month-Old Child.

Authors:  Motohiro Matsui; Mariko Shimizu; Aya Ioi; Azusa Mayumi; Kohei Higuchi; Akihisa Sawada; Maho Sato; Masahiro Yasui; Keiko Yanagihara; Masami Inoue
Journal:  Child Neurol Open       Date:  2016-04-04

7.  A New Observation of an Atypical and Severe Variant of the Guillain-Barre Syndrome in a Child: Remaining Challenges for Diagnosis, Nosologic Classification, and Therapeutic Course.

Authors:  Linda Pons; Véronique Manel; Dorothée Ville; Etienne Javouhey; Fabienne Bordet
Journal:  Child Neurol Open       Date:  2015-10-26

8.  Epidemiology of Guillain-Barré Syndrome in Iranian Children Aged 0-15 Years (2008-2013).

Authors:  Seyed Hassan Tonekaboni; Sussan Mahmoudi; Fatemeh Abdollah Gorji; Habibe Nejad Biglari; Mohammad Mahdi Taghdiri; Koroush Etemadi; Mohammad Ghofrani; Abdollah Karimi; Mohammad Rezaei Zadeh
Journal:  Iran J Child Neurol       Date:  2021
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.